Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Archimedes, Inc. Expands Use of Big Data in Healthcare Modeling and Analytics

Published: Thursday, March 28, 2013
Last Updated: Thursday, March 28, 2013
Bookmark and Share
New solutions incorporate additional real-world data sources to extend and customize modeling and analytic offerings.

Archimedes, Inc., a healthcare modeling and analytics company, announced today that it is substantially expanding its modeling and analytics solutions. New product offerings and disease models will enable users to more quickly and easily access and analyze information related to their complex questions. Archimedes customers will be able to further enhance their modeling and analytic projects by integrating their own electronic health records (EHR), claims, clinical trial, and pharmacokinetic/pharmacodynamic (PK/PD) simulation outcomes data with data from Archimedes simulations and proprietary algorithms. This integrated data will be accessed and analyzed through novel interfaces that offer near-instant results.

For more than ten years, the company has been working to proactively identify new opportunities where big data can play a role in the healthcare continuum – from research and development to the point of patient care. The advancements, which will become available throughout 2013, represent Archimedes’ continued commitment to its vision of revolutionizing medicine worldwide through mathematics.

“At Archimedes, we are dedicated to harnessing the power of big, real-world data by developing healthcare modeling and analytics tools,” said David Eddy, M.D., Ph.D. founder of Archimedes and pioneer in the area of evidenced-based medicine. “We are continually developing tools that can help researchers, life-science organizations, government agencies, payers, and providers get the most from the available data. Archimedes is excited to announce that, starting today, we will be providing free access through our website to new, easy-to-use tools for addressing some of healthcare’s most complex questions.”

Since inception, Archimedes has been striving to improve efficiencies in the healthcare system by developing quantitative methods for analyzing healthcare decisions at the individual and population levels. The tools, including the new ARCHeS Population Explorer, take modeling and analytics a step further by delivering big data to the fingertips of users, making it easier and faster to gather, enhance, and analyze multiple datasets. In the current era of accountability in medical decision making, it is critical that actionable data analytics tools are made available to the people who need them most.

The Archimedes Model is the most advanced mathematical modeling tool available to answer complex questions regarding health and healthcare. It is a clinically realistic, trial-validated, mathematical model of human physiology, diseases, interventions, and healthcare systems. By using advanced methods of mathematics, computing, and data systems, the Model enables researchers and decision makers to make better informed decisions. Archimedes continually validates the Model by comparing the results of simulated trials to the results of multinational clinical trials and cohort studies. The Model is the foundation behind the various solutions offered by Archimedes – including ARCHeS, the population-focused research platform, and IndiGO, the clinical-decision support tool for use by physicians and patients at the point-of-care.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos